On The Issue of Antibiotic Therapy for Lyme Disease
https://doi.org/10.37489/0235-2990-2025-70-7-8-92-100
EDN: XIGQOY
Abstract
Lyme disease (LD), or tick-borne borreliosis, annually affects thousands of people in different parts of the world, primarily the United States and Europe. At the same time, the issues of rational antimicrobial therapy of LD, which is aimed at achieving the desired effect while minimizing toxicity and adverse events, are becoming increasingly relevant. This review analyzes the literature data on the possibility of conducting short courses of antibiotic therapy for LD. The urgency of the problem under consideration necessitates further studies aimed at assessing treatment duration, with sufficient sample sizes and clearly defined treatment outcomes.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Boris S. Belov — D. Sc. in Medicine, Head of the Laboratory of Comorbid Infections and Vaccine Prevention, ResearcherID: ABD-2219-2020. eLIBRARY SPIN-code: 3298-4315. Scopus Author ID: 7004592537.
Moscow
Competing Interests:
none
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Lidia P. Ananyeva — D. Sc. in Medicine, Professor, Scientific Consultant at the Laboratory of Systemic Sclerosis. ResearcherID: U-7411-2017. eLIBRARY SPIN-code: 7182-3868. Scopus Author ID: 7004592537.
Moscow
Competing Interests:
none
References
1. Burn L., Tran T. M.P, Pilz A., Vyse A., Fletcher M. A., Angulo F. J. et al. Incidence of Lyme borreliosis in Europe from National surveillance systems (2005–2020). Vector Borne Zoonotic Dis. 2023; 23 (4): 156–171. doi: 10.1089/vbz.2022.0071.
2. Rudakova S. A., Teslova O. E., Mutalinova N. E., Pen’evskaya N. A., Blokh A. I., Rudakov N. V. et al. Review of the epidemiological situation on ixodic tick-borne borrelioses in the Russian Federation in 2013–2022 and forecast for 2023. Problemy osobo opasnykh infektsii. Problems of Particularly Dangerous Infections. 2023; 2: 75–87. doi: https://doi.org/10.21055/0370-1069-2023-2-75-87. (in Russian)
3. Gould L. H., Colby E., Pilz A., Brestrich G., Halsby K., Kelly P. H. et al. Lyme borreliosis awareness and risk perception: a survey in 20 European countries. Epidemiol Infect. 2025 Jan 23; 153: e29. doi: 10.1017/S0950268825000068.
4. Nguala S., Baux E., Patrat-Delon S., Saunier F., Schemoul J., Tattevin P. et al. Methodological quality assessment with the agree ii scale and a comparison of european and american guidelines for the treatment of lyme borreliosis: a systematic review. Pathogens. 2021; 10 (8): 972. doi: 10.3390/pathogens10080972.
5. Nemeth J., Bernasconi E., Heininger U., Abbas M., Nadal D., Strahm C. et al. For The Swiss Society for Infectious Diseases and The Swiss Society for Neurology. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016; 146: w14353. doi: 10.4414/smw.2016.14353.
6. Berende A., ter Hofstede H. J., Vos F. J., van Middendorp H., Vogelaar M. L., Tromp M. et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016; 374 (13): 1209–20. doi: 10.1056/NEJMoa1505425.
7. Fallon B. A., Keilp J. G., Corbera K. M., Petkova E., Britton C. B., Dwyer E. et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008; 70 (13): 992–1003. doi: 10.1212/01.WNL.0000284604.61160.2d.
8. Hunfeld K. P., Kraiczy P., Kekoukh E., Schäfer V., Brade V. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents possible implications for new therapeutic approaches to Lyme disease. Int J Med Microbiol. 2002; 291 Suppl 33: 125–37. doi: 10.1016/s1438-4221(02)80024-8.
9. Hunfeld K. P., Kraiczy P., Wichelhaus T. A., Schäfer V., Brade V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur J Clin Microbiol Infect Dis. 2000; 19 (1): 27–32. doi: 10.1007/s100960050005.
10. Hunfeld K. P., Wichelhaus T. A., Rödel R., Acker G., Brade V., Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother. 2004; 48 (1): 344–7. doi: 10.1128/AAC.48.1.344-347.2004
11. Agger W. A., Callister S. M., Jobe D. A. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother. 1992; 36 (8): 1788–90. doi: 10.1128/AAC.36.8.1788.
12. Verschoor Y. L., Vrijlandt A., Spijker R., van Hest R. M., Ter Hofstede H., van Kempen K. et al. Persistent Borrelia burgdorferi sensu lato infection after antibiotic treatment: systematic overview and appraisal of the current evidence from experimental animal models. Clin Microbiol Rev. 2022; 35 (4): e0007422. doi: 10.1128/cmr.00074-22.
13. Massarotti E. M., Luger S. W., Rahn D. W., Messner R. P., Wong J. B., Johnson R. C., Steere A. C. Treatment of early Lyme disease. Am J Med. 1992; 92 (4): 396–403. doi: 10.1016/0002-9343(92)90270-l.
14. Strle F., Preac-Mursic V., Cimperman J., Ruzic E., Maraspin V., Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993; 21 (2): 83–8. doi: 10.1007/BF01710737.
15. Luft B. J., Dattwyler R. J., Johnson R. C., Luger S. W., Bosler E. M., Rahn D. W. et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996; 124 (9): 785–91. doi: 10.7326/0003-4819124-9-199605010-00002.
16. Barsic B., Maretic T., Majerus L., Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection. 2000; 28 (3): 153–6. doi: 10.1007/s150100050069.
17. Wormser G. P., Ramanathan R., Nowakowski J., McKenna D., Holmgren D., Visintainer P. et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138 (9): 697–704. doi: 10.7326/0003-4819-138-9-200305060-00005.
18. Stupica D., Lusa L., Ruzić-Sabljić E., Cerar T., Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012; 55 (3): 343–50. doi: 10.1093/cid/cis402.
19. Stupica D., Collinet-Adler S., Blagus R., Gomišček A., Cerar Kišek T., Ružić-Sabljić E., Velušček M. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect Dis. 2023; 23 (3): 371–379. doi: 10.1016/S1473-3099(22)00528-X.
20. Arnez M., Radsel-Medvescek A., Pleterski-Rigler D., Ruzić-Sabljić E., Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 1999; 111 (22-23): 916–22.
21. Arnez M., Pleterski-Rigler D., Luznik-Bufon T., Ruzić-Sabljić E., Strle F. Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. Wien Klin Wochenschr. 2002; 114 (13-14): 498–504.
22. Nizič T., Velikanje E., Ružić-Sabljić E., Arnež M. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. Wien Klin Wochenschr. 2012; 124 (13–14): 427–33. doi: 10.1007/s00508-012-0194-1.
23. Arnež M., Ružić-Sabljić E. Azithromycin Is Equally Effective as Amoxicillin in Children with Solitary Erythema Migrans. Pediatr Infect Dis J. 2015; 34 (10): 1045–8. doi: 10.1097/INF.0000000000000804.
24. Pfister H. W., Preac-Mursic V., Wilske B., Einhäupl K. M. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch Neurol. 1989; 46 (11): 1190–4. doi: 10.1001/archneur.1989.00520470044025.
25. Pfister H. W., Preac-Mursic V., Wilske B., Schielke E., Sörgel F., Einhäupl K. M. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis. 1991; 163 (2): 311–8. doi: 10.1093/infdis/163.2.311.
26. Müllegger R. R., Millner M. M., Stanek G., Spork K. D. Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children — a prospective study. Infection. 1991; 19 (4): 279–83. doi: 10.1007/BF01644967.
27. Karlsson M., Hammers-Berggren S., Lindquist L., Stiernstedt G., Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology. 1994; 44 (7): 1203–7. doi: 10.1212/wnl.44.7.1203.
28. Oksi J., Nikoskelainen J., Hiekkanen H., Lauhio A., Peltomaa M., Pitkäranta A. et al. Duration of antibiotic treatment in disseminated Lyme borreliosis: a double-blind, randomized, placebo-controlled, multicenter clinical study. Eur J Clin Microbiol Infect Dis. 2007; 26 (8): 571–81. doi: 10.1007/s10096-007-0340-2.
29. Solheim A. M., Lorentzen Å. R., Dahlberg A. O., Flemmen H. Ø., Brune S., Forselv K. J. N. et al. Six versus 2 weeks treatment with doxycycline in European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blinded, randomised and placebo-controlled trial. J Neurol Neurosurg Psychiatry. 2022 Jul 27; 93 (11): 1222–8. doi: 10.1136/jnnp-2022-329724.
30. Steere A. C., Green J., Schoen R. T., Taylor E., Hutchinson G. J., Rahn D. W., Malawista S. E. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med. 1985; 312 (14): 869–74. doi: 10.1056/NEJM198504043121401.
31. Hassler D., Zöller L., Haude M., Hufnagel H. D., Heinrich F., Sonntag H. G. Cefotaxime versus penicillin in the late stage of Lyme disease prospective, randomized therapeutic study. Infection. 1990; 18 (1): 16–20. doi: 10.1007/BF01644175.
32. Dattwyler R. J., Halperin J. J., Volkman D. J., Luft B. J. Treatment of late Lyme borreliosis randomised comparison of ceftriaxone and penicillin. Lancet. 1988; 1 (8596): 1191–4. doi: 10.1016/s0140-6736(88)92011-9.
33. Raffetin A., Henningsson A. J., Ornstein K., Arias P., Fingerle V., PatratDelon S., et al. Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis. Infection. 2025; 53 (3): 809–830. doi: 10.1007/s15010-025-02501-3. Epub 2025 Apr 17. PMID: 40246800.
34. Weber K., Preac-Mursic V., Wilske B., Thurmayr R., Neubert U., Scherwitz C. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. Infection.; 18 (2): 91–6. doi: 10.1007/BF01641422. PMID: 2185158.
35. Weber K., Wilske B., Preac-Mursic V., Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection. 1993; 21 (6): 367–72. doi: 10.1007/BF01728915.
36. Eliassen K. E., Reiso H., Berild D., Lindbæk M. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect. 2018; 24 (12): 1290–1296. doi: 10.1016/j.cmi.2018.02.028.
37. Dattwyler R. J., Luft B. J., Kunkel M. J., Finkel M. F., Wormser G. P., Rush T. J. et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997; 337 (5): 289–294. doi: 10.1056/NEJM199707313370501.
38. Stupica D., Velušcek M., Blagus R., Bogovic P., Rojko T., Cerar T., Strle F. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. J Antimicrob Chemother. 2018; 73 (5): 1352–1358. doi: 10.1093/jac/dkx534.
39. Borg R., Dotevall L., Hagberg L., Maraspin V., Lotric-Furlan S., Cimperman J., Strle F. Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis. Scand J Infect Dis. 2005; 37 (6-7): 449–54. doi: 10.1080/00365540510027228.
40. Ljøstad U., Skogvoll E., Eikeland R., Midgard R., Skarpaas T., Berg A., Mygland A. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008; 7 (8): 690–5. doi: 10.1016/S14744422(08)70119-4.
41. Kortela E., Kanerva M. J., Puustinen J., Hurme S., Airas L., Lauhio A. et al. Oral Doxycycline Compared to Intravenous Ceftriaxone in the Treatment of Lyme Neuroborreliosis: A Multicenter, Equivalence, Randomized, Open-label Trial. Clin Infect Dis. 2021; 72 (8): 1323–1331. doi: 10.1093/cid/ciaa217.
42. Caperton E. M., Heim-Duthoy K. L., Matzke G. R., Peterson P. K., Johnson R. C. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo-controlled trial. Arch Intern Med. 1990; 150 (8): 1677–82.
43. Dattwyler R. J., Wormser G. P., Rush T. J., Finkel M. F., Schoen R. T., Grunwaldt E., et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr. 2005; 117 (11–12): 393–397. doi: 10.1007/s00508-005-0361-8.
44. Glatz M., Resinger A., Semmelweis K., Ambros-Rudolph C. M., Müllegger R. R. Clinical spectrum of skin manifestations of Lyme borreliosis in 204 children in Austria. Acta Derm Venereol. 2015; 95 (5): 565–71. doi: 10.2340/00015555-2000.
45. Shen R. V., McCarthy C. A., Smith R. P. Lyme Carditis in hospitalized children and adults, a case series. Open Forum Infect Dis. 2021; 8 (7): ofab140. doi: 10.1093/ofid/ofab140.
46. Sauer A., Speeg-Schatz C., Hansmann Y. Two cases of orbital myositis as a rare feature of lyme borreliosis. Case Rep Infect Dis. 2011; 2011: 372470. doi: 10.1155/2011/372470.
47. Aberer E., Breier F., Stanek G., Schmidt B. Success and failure in the treatment of acrodermatitis chronica atrophicans. Infection. 1996; 24 (1): 85–87. doi: 10.1007/BF01780666.
48. Roca Mora M. M., Cunha L. M., Godoi A., Donadon I., Clemente M., Marcolin P. et al. Shorter versus longer duration of antimicrobial therapy for early Lyme disease: A systematic review and meta-analysis. Diagn Microbiol Infect Dis. 2024; 109 (2): 116215. doi: 10.1016/j.diagmicrobio.2024.116215.
49. Arvikar S. L., Steere A. C. Lyme Arthritis. Infect Dis Clin North Am. 2022 Sep; 36 (3): 563–577. doi: 10.1016/j.idc.2022.03.006.
50. Coumou J., Herkes E. A., Brouwer M. C., van de Beek D., Tas S. W., Casteelen G. et al. Ticking the right boxes: classification of patients suspected of Lyme borreliosis at an academic referral center in the Netherlands. Clin Microbiol Infect. 2015; 21 (4): 368.e11–20. doi: 10.1016/j.cmi.2014.11.014.
51. Gynthersen R. M.M, Tetens M. M., Ørbæk M., Haahr R., Fana V., Hansen K. et al. Classification of patients referred under suspicion of tick-borne diseases, Copenhagen, Denmark. Ticks Tick Borne Dis. 2021; 12 (1): 101591. doi: 10.1016/j.ttbdis.2020.101591.
52. Raffetin A., Schemoul J., Chahour A., Nguala S., Caraux-Paz P., Paoletti G. et al. On the behalf of the tick-borne diseases reference center-paris and northern region working group. multidisciplinary management of suspected lyme borreliosis: clinical features of 569 patients, and factors associated with recovery at 3 and 12 months, a prospective cohort study. Microorganisms. 2022; 10 (3): 607. doi: 10.3390/microorganisms10030607.
Review
For citations:
Belov BS, Ananyeva LP. On The Issue of Antibiotic Therapy for Lyme Disease. Antibiotiki i Khimioterapiya = Antibiotics and Chemotherapy. 2025;70(7-8):92-100. (In Russ.) https://doi.org/10.37489/0235-2990-2025-70-7-8-92-100. EDN: XIGQOY
Views:
6
Email this article 